A 35-year-old woman with systemic lupus erythematosus (SLE) is started on mycophenolate mofetil (MMF) for lupus nephritis. After 3 weeks of therapy, she develops severe diarrhea and abdominal pain. Which investigation is most appropriate to confirm the suspected adverse effect?

Explanation

## Investigation of Choice for MMF-Related GI Adverse Effects ### Clinical Context Mycophenolate mofetil (MMF) is a selective inhibitor of inosine monophosphate dehydrogenase (IMPDH) type II, widely used for lupus nephritis and transplant immunosuppression. Gastrointestinal toxicity — including diarrhea, abdominal pain, and colitis — is a well-recognized adverse effect. The key diagnostic challenge is distinguishing **MMF-induced colitis** from infectious colitis, inflammatory bowel disease, or other drug-related causes. ### Why Colonoscopy with Mucosal Biopsy? **Key Point:** MMF can cause a distinct pattern of mucosal injury (MMF-associated colitis/enteropathy) characterized by crypt apoptosis, architectural distortion, and inflammatory infiltrate — findings that are only confirmable on **histopathology**. Colonoscopy with mucosal biopsy is the gold standard to **confirm** the suspected adverse effect. **High-Yield:** The histological pattern of MMF-induced colitis (increased crypt apoptosis, graft-versus-host disease-like changes) is pathognomonic and distinguishes it from infectious or idiopathic inflammatory bowel disease. This is well-described in Harrison's Principles of Internal Medicine and gastroenterology literature. ### Diagnostic Approach | Investigation | Purpose | Limitation | |---|---|---| | **Colonoscopy with mucosal biopsy** | Confirms MMF-induced mucosal injury histologically | Invasive, but gold standard for confirmation | | Plasma MPA concentration | Measures drug exposure; guides dose adjustment | Does not confirm the nature of mucosal injury; TDM thresholds for GI toxicity are not universally validated | | Fecal calprotectin + stool culture | Screens for infection/inflammation | Non-specific; cannot confirm drug-induced colitis | | IMPDH activity assay | Research tool for pharmacodynamic monitoring | Not used in routine clinical practice | **Clinical Pearl:** While plasma MPA levels (TDM) can guide dose adjustment, they do not **confirm** the diagnosis of MMF-induced colitis — elevated MPA levels are neither sensitive nor specific for GI mucosal injury. The stem specifically asks for the investigation to **confirm the suspected adverse effect**, making colonoscopy with biopsy the correct answer. ### Why Not Plasma MPA Concentration? - TDM of MPA is useful for optimizing immunosuppression efficacy and avoiding over-immunosuppression, but the correlation between MPA AUC and GI toxicity is inconsistent across studies. - Elevated MPA levels do not confirm mucosal injury; a patient can have GI symptoms from other causes even with therapeutic MPA levels. - Confirmation of MMF-induced colitis requires histological evidence. [cite: Harrison's Principles of Internal Medicine, 21e, Ch. 354; Iacucci M et al., "Mycophenolate mofetil-induced colitis," Endoscopy 2012]